AOP Orphan and PharmaEssentia Announce Latest Clinical Results for Ropeginterferon alfa-2b in Polycythemia Vera

Based on data from three abstracts (EHA-3520, EHA-3556, and EHA-1564) presented recently at the 22nd Congress of the European Hematology Association, the faculty concluded that long-term maintenance treatment of polycythemia vera patients with ropeginterferon alfa-2b administered every 4 weeks is feasible, efficacious, and well tolerated. 

 PR Newswire

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.